Multicenter randomized phase II study of docetaxel (Doc) given q3w vs q1w plus trastuzumab (Tra) as first line therapy for HER2 overexpressing adjuvant anthracyclin pretreated metastatic breast cancer (MBC).

被引：0
|
作者：
Raab, G
Brugger, W
Harbeck, N
Heidemann, E
Schaller, G
Wallwiener, D
Bacchus, L
Eidtmann, H
Friese, K
Goebel, R
Hilfrich, J
Hoeffken, K
Kreienberg, R
Kuhn, R
Loehr, W
Nitz, U
Wolf, H
Buechele, T
Eiermann, E
De Wit, M
机构：
[1] Frauenklin Roten Kreuz, Munich, Germany
[2] Klinikum Villingen Schwenningen, Villigen, Switzerland
[3] Tech Univ Munich, Klinikum Rechts Isar, D-8000 Munich, Germany
[4] Diakonissen Hosp, Stuttgart, Germany
[5] Univ Hosp Benjamin Franklin, Berlin, Germany
[6] Univ Tubingen, Tubingen, Germany
[7] Robert Bosch Krankenhaus, Stuttgart, Germany
[8] Univ Eppendorf, Hamburg, Germany
[9] Univ Kiel, D-24098 Kiel, Germany
[10] Univ Rostock, D-2500 Rostock, Germany
[11] Evang Krankenhaus, Oberhausen, Germany
[12] Krankenhaus Henriettenstiftung, Hannover, Germany
[13] Univ Jena, D-6900 Jena, Germany
[14] Univ Ulm, D-89069 Ulm, Germany
[15] Univ Bonn, D-5300 Bonn, Germany
[16] Dr Horst Schmidt Kliniken, Wiesbaden, Germany
[17] Univ Dusseldorf, D-4000 Dusseldorf, Germany
[18] Kreiskrankenhaus, Leonberg, Germany
[19] Aventis Pharma Germay, Bad Soden, Germany
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2002年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
443
引用
收藏
页码：S114 / S114
页数：1
相关论文
共 50 条
  • [1] A randomized phase 2 trial of qw or q3w ABI-007 (ABX) vs. q3W solvent-based docetaxel (TXT) as first-line therapy in metastatic breast cancer (MBC).
    Gradishar, W.
    Krasnojon, D.
    Cheporov, S.
    Makhson, A.
    Manikhas, G.
    Hawkins, M. J.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S21 - S21
  • [2] Cost utility analysis of nab-paclitaxel weekly or q3w compared with docetaxel q3w as first-line therapy in metastatic breast cancer (MBC)
    Dranitsaris, G.
    Perayre Badia, M.
    Clopes, A.
    Fernandez Ortega, M.
    Rey Salido, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC)
    Gradishar, W.
    Krasnojon, D.
    Cheporov, S.
    Makhson, A.
    Manikhas, G.
    Clawson, A.
    Hawkins, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Nab-paclitaxel weekly or q3w compared to docetaxel q3w as first-line therapy in patients with metastatic breast cancer: An economic analysis of a prospective randomized trial
    Dranitsaris, G.
    Coleman, R.
    Gradishar, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2
    Servitja, Sonia
    Ramos, Manuel
    Gil, Miguel
    Sanchez-Rovira, Pedro
    Vazquez-Estevez, Sergio
    Antonio Virizuela, Jose
    Garcia-Estevez, Laura
    Velasco, Amalia
    Tusquets, Ignacio
    ANTI-CANCER DRUGS, 2012, 23 (02) : 239 - 246
  • [6] Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes
    Lee, Yu Rim
    Huh, Seok Jae
    Lee, Dong Hyun
    Yoon, Hyun Hwa
    Seol, Young-Mi
    Choi, Young-Jin
    Kwon, Kyung A.
    Lee, Suee
    Oh, Sung Yong
    Kim, Sung-Hyun
    Kim, Hyo-Jin
    Kwon, Hyuk-Chan
    JOURNAL OF BREAST CANCER, 2011, 14 (02) : 140 - 146
  • [7] BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)
    Pienkowski, Tadeusz
    Forbes, John
    Valero, Vicente
    Eiermann, Wolfgang
    Von Minckwitz, Gunter
    Martin, Miguel
    Smylie, Michael
    Crown, John
    Noel, Nathalie
    Pegram, Mark
    ANNALS OF ONCOLOGY, 2006, 17 : 71 - 71
  • [8] Nab-paclitaxel weekly or Q3w compared to docetaxel Q3w as first-line therapy in patients with metastatic breast cancer (MBC): an economic analysis of a prospective randomized trial from the perspective of the German health care system
    Dranitsaris, G.
    Schoening, T.
    EJC SUPPLEMENTS, 2009, 7 (02): : 280 - 280
  • [9] BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC)
    Forbes, J. F.
    Pienkowski, T.
    Valero, V.
    Eiermann, W.
    Von Minckwitz, G.
    Martin, M.
    Smylie, M.
    Dr, J. M. Crown
    Noel, N.
    Pegram, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 932S - 932S
  • [10] Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer
    Venturini, M
    Bighin, C
    Monfardini, S
    Cappuzzo, F
    Olmeo, N
    Durando, A
    Puglisi, F
    Nicoletto, O
    Lambiase, A
    Del Mastro, L
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 95 (01) : 45 - 53
12345